

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

**RESULTS OF ANNUAL GENERAL MEETING**

The results of the Ordinary General Meeting are set out in the table below:

Resolutions	Votes For		Votes Against		Result
	Number	%	Number	%	
1) Approval of the Company's individual financial statements for the year ended 31 December 2021 ( <b>Resolution No. 1</b> ),	8,894,000	91.27	850,773	8.73	Adopted
2) Approval of the Company's consolidated financial statements for the year ended 31 December 2021 ( <b>Resolution No. 2</b> ),	5,981,752	65.88	3,097,785	34.12	Adopted
3) Allocation of the Company's loss for the year ended 31 December 2021 ( <b>Resolution No. 3</b> ),	8,860,326	90.52	928,247	9.48	Adopted
4) Authorization of the related parties agreements referred to in Articles L. 225-38 <i>et seq.</i> of the French Commercial Code ( <b>Resolution No. 4</b> ),	8,844,307	90.98	876,644	9.02	Adopted
5) Discharge to the Board of Directors ( <b>Resolution No. 5</b> ),	8,373,733	86.03	1,359,369	13.97	Adopted
6) Authorisation for the Company to buy back its own shares ( <b>Resolution No. 6</b> ),	8,061,152	83.68	1,571,919	16.32	Adopted
7) Ratification of the appointment of a member of the Board of Directors ( <b>Resolution No. 7</b> ),	8,362,464	86.57	1,297,696	13.43	Adopted
8) Amount of remuneration allocated to members of the Board of Directors for the year ended 31 December 2021 ( <b>Resolution No. 8</b> ),	7,685,030	79.05	2,036,561	20.95	Adopted
9) Amount of remuneration to be allocated to members of the Board of Directors from 1 January 2022 ( <b>Resolution No. 9</b> ),	7,517,452	77.35	2,201,807	22.65	Adopted
10) Powers for formalities ( <b>Resolution No. 10</b> ).	8,583,024	87.51	1,225,208	12.49	Adopted

Number of participating shareholders (by voting form, electronic vote, proxy or present): 1,225 shareholders representing 10,007,703 shares.

- End -

**For further information, please refer to [www.novacyt.com](http://www.novacyt.com) or contact:**

**Novacyt SA**

David Allmond, Chief Executive Officer  
James McCarthy, Chief Financial Officer  
+44 (0)1276 600081

**SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)  
+44 (0)20 3470 0470

**Numis Securities Limited (Joint Broker)**

Freddie Barnfield / James Black  
+44 (0)20 7260 1000

**Allegra Finance (French Listing Sponsor)**

Rémi Durgetto / Yannick Petit  
+33 (1) 42 22 10 10  
[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

**FTI Consulting (International)**

Victoria Foster Mitchell / Alex Shaw  
+44 (0)20 3727 1000  
[victoria.fostermitchell@fticonsulting.com](mailto:victoria.fostermitchell@fticonsulting.com) / [Alex.Shaw@fticonsulting.com](mailto:Alex.Shaw@fticonsulting.com)

**FTI Consulting (France)**

Arnaud de Cheffontaines  
+33 (0)147 03 69 48  
[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)

**About Novacyt Group**

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)